

SEQUENCE LISTING

<110> Genmab A/S

<120> METHODS OF TREATING CANCER WITH A COMBINATION OF A
PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE

<130> 76168-20006.40

<140> Not Yet Assigned

<141> Concurrently Herewith

<150> US 62/753,730

<151> 2018-10-31

<150> US 62/646,256

<151> 2018-03-21

<160> 16

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Construct

<400> 1

Gly Phe Thr Phe Ser Asn Tyr Ala
1 5

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Construct

<400> 2

Ile Ser Gly Ser Gly Asp Tyr Thr
1 5

<210> 3

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Construct

<400> 3

Ala Arg Ser Pro Trp Gly Tyr Tyr Leu Asp Ser
1 5 10

<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 4
Gln Gly Ile Ser Ser Arg
1 5

<210> 5
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 5
Ala Ala Ser
1

<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 6
Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr
1 5

<210> 7
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 7
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Ser Gly Ser Gly Asp Tyr Thr Tyr Thr Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Ser Pro Trp Gly Tyr Tyr Leu Asp Ser Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115

<210> 8
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 8
Asp Ile Gln Met Thr Gln Ser Pro Pro Ser Leu Ser Ala Ser Ala Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Arg
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 9
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 9
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser
20 25

<210> 10
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 10
Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser
1 5 10 15
Ser

<210> 11
<211> 38
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 11
Tyr Tyr Thr Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
1 5 10 15
Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
20 25 30
Thr Ala Val Tyr Tyr Cys
35

<210> 12
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 12
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1 5 10

<210> 13
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 13
Asp Ile Gln Met Thr Gln Ser Pro Pro Ser Leu Ser Ala Ser Ala Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser
20 25

<210> 14
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 14
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile
1 5 10 15
Tyr

<210> 15

<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 15
Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
1 5 10 15
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala
20 25 30
Thr Tyr Tyr Cys
35

<210> 16
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 16
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
1 5 10